Leaders at the annual meeting of the American Academy of Neurology recently announced some important progress that has been made with regard to understanding and treating amyotrophic lateral sclerosis (ALS).
Organizers of the One Brave Idea research funding opportunity recently announced the 10 finalists who have been chosen for the last round of the competition, which gives the winner $75 million for research.
Researchers recently evaluated the brain differences between male and female worms to determine how the sexually dimorphic connections -- those which occur in either males or females -- develop inside the nervous system.
The goal of the Parker Institute for Cancer Immunotherapy is to accelerate the development of cutting-edge immune therapies capable of turning cancer into a curable disease by ensuring the collaboration of the field’s top researchers and quickly converting their findings into patient treatments.
Officials are Takeda Pharmaceutical Company Limited recently released the results from its randomized, international, placebo-controlled, double-blind, phase-three trial for Ninlaro, the first oral proteasome inhibitor.
Leaders at the U.S. Food and Drug Administration (FDA) recently granted approval of Xalkori to treat patients who have advanced (metastatic) non-small cell lung cancer (NSCLC) and tumors with an ROS-1 gene alteration.
The ALS Association recently published a new report, called 'Medicines in Development for Rare Diseases,' to show that U.S. biopharmaceutical research companies are working hard to create new medicines for rare diseases.
The FDA recently expanded the label for Imbruvica (ibrutinib) to include data that show the overall survival increases for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Leaders at the American Heart Association recently reported that peripheral artery disease (PAD) patients who take statins, which are meant to lower cholesterol, may have a lower risk of death and amputation compared to patients without statins.